Drug intelligence / Profile preview

APH-1701

Development stage: Preclinical
Lead developer: Aphios
Modality: Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems
Administration: Intravenous

Overview

APH-1701 is an experimental nanotherapeutic developed by Aphios for the treatment of HIV-Associated Neurocognitive Disorders (HAND) and other neuroinflammatory conditions. It consists of small interfering RNA (siRNA) encapsulated in proprietary polymer-lipid nanosomes using Aphios' Phospho-Nanosome (PNS) technology. The siRNA is designed to silence the expression of C-C motif chemokine receptor 2 (CCR2) on monocytes and macrophages. By downregulating CCR2, the drug aims to inhibit the migration of these inflammatory cells across the blood-brain barrier and into the central nervous system, thereby reducing neuroinflammation and the cognitive decline typically observed in NeuroAIDS.

Other names: APH-1701-Aphios-CCR2-nanosiRNAAPH1701-Aphios-CCR2-nanosiRNAAPH 1701-Aphios-CCR2-nanosiRNACCR2-nanosiRNACCR-2-nanosiRNACCR 2-nanosiRNA

Targets

CCR2 (Chemokine (C-C motif) Receptor 2)

Beyond the preview

Go deeper on APH-1701.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on APH-1701.

Explore the full profile